Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) FCF Margin (2022 - 2025)

Historic FCF Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to 143.52%.

  • InMed Pharmaceuticals' FCF Margin rose 9300.0% to 143.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 157.31%, marking a year-over-year decrease of 234800.0%. This contributed to the annual value of 157.14% for FY2025, which is 50000.0% down from last year.
  • As of Q3 2025, InMed Pharmaceuticals' FCF Margin stood at 143.52%, which was up 9300.0% from 136.31% recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' FCF Margin peaked at 29.85% during Q2 2023, and registered a low of 1728.88% during Q1 2022.
  • Over the past 5 years, InMed Pharmaceuticals' median FCF Margin value was 162.59% (recorded in 2024), while the average stood at 415.89%.
  • Per our database at Business Quant, InMed Pharmaceuticals' FCF Margin soared by 15686500bps in 2023 and then crashed by -760500bps in 2024.
  • InMed Pharmaceuticals' FCF Margin (Quarter) stood at 1252.16% in 2021, then skyrocketed by 54bps to 577.52% in 2022, then soared by 74bps to 149.02% in 2023, then tumbled by -51bps to 225.07% in 2024, then skyrocketed by 36bps to 143.52% in 2025.
  • Its FCF Margin stands at 143.52% for Q3 2025, versus 136.31% for Q2 2025 and 131.54% for Q1 2025.